Lifecore Biomedical, Inc.

NASDAQ:LFCR

Drug Manufacturers - Specialty & Generic

Healthcare
$6.40 +0.27%

+$0.02 today

Market cap
$242.60M
Beta
1.07
P/E (TTM)
-6.1
EPS (TTM)
-$0.91
52W Low $3.63High $8.98

Volume 0.15M

Average 0.29M

LFCR Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Lifecore Biomedical, Inc.NASDAQ: LFCR

Operating Income · Q3 FY2026 · quarter ended Mar 2026

Operating income of -$4.67M in Q3 FY2026

Q3 FY2026 operating income was -$4.67M. Trailing-twelve-month operating income was -$78K.

Context

  • Operating income amounted to 13.4% of revenue in FY2025, up 6.5 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 1 analysts of -$9.28M (+46.2%) for the fiscal year ending May 2026, a step up from the -95.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.67M-300.2% QoQ
Last fiscal yearMay 2025
-$17.25M-95.0% YoY
LTMMar 2026
-$78K— YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-95.0%+46.2%+141.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(17.25M) USD
Year-over-year change
-95.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How LFCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Operating income amounts to 0.1% of revenue for LFCR, versus a peer median of 64.7%.
LFCR Competitors
Operating Income for LFCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$789.11K CAD-84.1%—0.3%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$78K USD——0.1%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$16.31M USD+29.5%—39.0%
SGHTSight Sciences, Inc.LTM Mar 2026-$35.65M USD+28.2%—44.8%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€46.45M EUR-39.8%—345.5%
CVRXCVRx, Inc.LTM Mar 2026-$49.99M USD+1.4%—84.6%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026-$52.45M USD-14.1%——
BIOABioAge Labs, Inc.LTM Mar 2026-$101.71M USD-24.3%—985.9%
CGCCanopy Growth CorporationLTM Mar 2026-CA$103.15M CAD+11.9%—33.0%
IMMPImmutep LimitedFY2025-A$126.42M AUD-43.5%—2506.5%
Peer median (excluding LFCR) —-14.1%—64.7%

Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
May 2021
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
Revenue100.87M111.27M103.27M128.26M128.87M
Cost of Revenue61.94M72.2M75.28M86.41M88.57M
Gross Profit38.94M39.07M27.99M41.85M40.3M
Gross Margin38.6%35.1%27.1%32.6%31.3%
Research & Development6.68M7.84M8.74M8.58M8.26M
Selling, General & Admin27.72M34.66M38.97M40.46M44.05M
Operating Expenses47.76M50.86M49.78M50.69M57.54M
Depreciation & Amortization19.87M18.06M13.18M8M8.03M
EBITDA(987K)12.84M(33.17M)35.6M(8.81M)
EBITDA Margin-1.0%11.5%-32.1%27.8%-6.8%
Operating Income(8.82M)(11.79M)(21.8M)(8.84M)(17.25M)
Operating Margin-8.7%-10.6%-21.1%-6.9%-13.4%
Interest Income48K81K68K00
Interest Expense8.93M15.55M17.65M18.09M21.84M
Other Income / Expenses(20.96M)(8.9M)(42.13M)18.36M(21.43M)
Income Before Tax(29.79M)(20.69M)(63.93M)9.51M(38.67M)
Pre-Tax Margin-29.5%-18.6%-61.9%7.4%-30.0%
Income Tax Expense(6.35M)(5.21M)308K183K43K
Net Income(32.29M)(116.72M)(99.56M)12.01M(38.72M)
Net Margin-32.0%-104.9%-96.4%9.4%-30.0%
EPS (Basic)(1.12)(3.97)(3.32)0.39(1.27)
EPS (Diluted)(1.12)(3.97)(3.32)0.33(1.27)
Weighted Avg Shares29.29M29.47M29.96M30.47M34.82M
Weighted Avg Shares (Diluted)29.29M29.47M29.96M36.66M34.82M

Lifecore Biomedical, Inc.

NASDAQ:LFCR

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.